Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke
Overview
- Phase
- Phase 4
- Intervention
- porcine brain peptide (Cerebrolysin)
- Conditions
- Cerebrolysin
- Sponsor
- Samsung Medical Center
- Enrollment
- 71
- Locations
- 1
- Primary Endpoint
- the improvement ratio of Fugl-Meyer assessment
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke.
Investigators
Yun-Hee Kim
Yun-Hee Kim
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •1st cortical or subcortical unilateral infarction (supratentorial lesion)
- •Confirmed by CT or MRI
- •Subacute stage: less than 1 week
- •Moderate to severe motor function involvement-total of FMA: 0-84
- •Age: between 18 and 80 years
Exclusion Criteria
- •Progressive or unstable stroke
- •Pre-existing and active major neurological disease
- •Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia
- •A history of significant alcohol or drug abuse in the prior 3 years
- •Advanced liver, kidney, cardiac, or pulmonary disease
- •A terminal medical diagnosis consistent with survival \< 1 year
- •Substantial decrease in alertness at the time of randomization, defined as score of 2 on NIH Stroke Scale
- •Pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years
- •Any condition that would represent a contraindication to Cerebrolysin, including allergy to Cerebrolysin
- •Current enrolment in another therapeutic study of stroke or stroke recovery
Arms & Interventions
Study Group 1
Study Group 1: 30ml Cerebrolysin
Intervention: porcine brain peptide (Cerebrolysin)
Study Group 2
Study Group 2: Placebo (0.9% NaCl)
Intervention: Placebo
Outcomes
Primary Outcomes
the improvement ratio of Fugl-Meyer assessment
Time Frame: after 3 weeks
Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke